Adrenal Disorders

>

Latest News

Atumelnant for Congenital Adrenal Hyperplasia Agent Granted FDA Orphan Drug Designation / ©pikovit/stock.adobe.com
Atumelnant for Congenital Adrenal Hyperplasia Agent Granted FDA Orphan Drug Designation

August 21st 2025

The FDA's ODD award is based on the positive findings from the phase 2 TouCAHn trial, which also support Crinetics' robust phase 3 pivotal clinical trial program for the novel agent.

New Data Highlight Significant Challenges to Managing CAH: Daily Dose / image credit: ©New Africa/AdobeStock
New Data Highlight Significant Challenges to Managing CAH: Daily Dose

August 1st 2025

ENDO 2025: Most Patients With Classic Congenital Adrenal Hyperplasia Experience High Glucocorticoid Exposure or Suboptimal Control / Image credit: ©Osada/AdobeStock
ENDO 2025: Most Patients With Classic Congenital Adrenal Hyperplasia Experience High Glucocorticoid Exposure or Suboptimal Control

July 15th 2025

FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia / image credit ©pivovit/stock.adobe.com
FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia

June 24th 2025

More News

7 New Drugs Approved for Primary Care: Q4 2024 / Image credit: ©Graphic Master/AdobeStock

7 Drugs Approved for Primary Care: Q4 2024

Sydney Jennings
January 31st 2025

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

© 2025 MJH Life Sciences

All rights reserved.